[7]. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J].N Engl J Med. 2021 Oct 14;385(16):1451-1461.[8]. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098...
近期,JACC: HEART FAILURE杂志发表了一篇期刊述评文章,在不断发展的证据背景下讨论这些概念。让我们一起来看看吧! 对于HFrEF患者, 建议将四联疗法作为起始治疗 根据2022年美国心脏病学会(ACC)/美国心脏协会(AHA)/美国心力衰竭协会心力衰竭(HF)指南,启动肾素-血管紧张素系统抑制剂的四联疗法,包括血管紧张素转换酶抑制剂...
近期,JACC: HEART FAILURE杂志发表了一篇期刊述评文章,在不断发展的证据背景下讨论这些概念。让我们一起来看看吧! 对于HFrEF患者, 建议将四联疗法作为起始治疗 根据2022年美国心脏病学会(ACC)/美国心脏协会(AHA)/美国心力衰竭协会心力衰竭(HF)指南,启动肾素-...
[8]. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. [9]. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines ...
参考文献Gianluigi Savarese et al. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation:A Multinational Observational Study (EVOLUTION HF). JACC Heart Failure. 2023 Jan;11(1):1-14. doi: 10.1016/j.jchf.2022.08.009. Epub 2022 Sep 7....
[5]. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. [6]. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection...
[7]. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J].N Engl J Med. 2021 Oct 14;385(16):1451-1461. [8]. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-109...
The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.#Use of ...
Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality, increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept of high...
[4]. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. A Report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol. 2022-4-1. [5]. Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the Soluble Guanylate Cyclase...